VYNE Therapeutics (VYNE) Q3 2024 earnings summary

Executive summary

• Focused on developing BET inhibitors for chronic inflammatory and immune-mediated conditions, with lead programs VYN201 (topical) and VYN202 (oral) advancing in clinical trials.

• VYN201 Phase 2b vitiligo trial exceeded enrollment target; full enrollment expected December 2024, topline results mid-2025.

• Initiated Phase 2b trial for VYN201 and Phase 1a SAD/MAD trial for VYN202, with positive SAD data and further results expected in late 2024.

• Pipeline progress highlights strong momentum in clinical programs for immune-mediated diseases.

• Net loss of $27.8 million for the nine months ended September 30, 2024, reflecting increased R&D investment.

Financial highlights

• Cash, cash equivalents, restricted cash, and marketable securities totaled $70.2 million as of September 30, 2024.

• Royalty revenues were $0.1 million for the quarter and $0.4 million for the nine months, up 19.8% year-over-year.

• Research and development expenses rose 208.9% to $10.2 million for the quarter and 60.1% to $21.3 million for the nine months, driven by clinical trial activity.

• General and administrative expenses were stable at $3.0 million for the quarter and $10.0 million for the nine months.

• Net loss for Q3 2024 was $12.2 million, or $0.29 per share, compared to $6.6 million, or $2.01 per share, in Q3 2023.

Outlook and guidance

• Topline results from the VYN201 Phase 2b trial expected in mid-2025; VYN202 MAD trial results expected in Q4 2024.

• Plans to initiate Phase 1b trials for VYN202 in psoriasis and rheumatoid arthritis, with results anticipated in the second half of 2025.

• Cash position expected to fund operations through end of 2025.

• Expects to require substantial additional capital for continued development and operations beyond current liquidity.